Bank of America
RXRX icon

Bank of America’s Recursion Pharmaceuticals RXRX Stock Holding History

Bank of America’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-437,900
Closed -$2.14M – 8196
2025
Q3 		$2.14M Sell
437,900
-79,000
-15% -$415K ﹤0.01% 4772
2025
Q2 		$2.62M Buy
516,900
+309,900
+150% +$1.52M ﹤0.01% 4530
2025
Q1 		$1.1M Sell
207,000
-151,700
-42% -$1.11M ﹤0.01% 5156
2024
Q4 		$2.42M Buy
358,700
+222,500
+163% +$1.5M ﹤0.01% 4281
2024
Q3 		$898K Buy
+136,200
New +$976K ﹤0.01% 5118

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Bank of America's RXRX Position: Q1 2026 in Review

Bank of America increased its Recursion Pharmaceuticals (RXRX) stake by 18% in Q1 2026, buying an estimated $1.49M and bringing the position to 2,496,831 shares worth $7.67M. The position accounts for ﹤0.01% of the portfolio, ranked #3151.

Bank of America first reported a position in RXRX in Q2 2021 and has held it in 20 quarters since. The position peaked at $17M in Q1 2024. 335 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

  • Bank of America held 2,496,831 shares of Recursion Pharmaceuticals worth $7.67M as of Q1 2026.
  • Bank of America bought 384,486 Recursion Pharmaceuticals shares in Q1 2026, an estimated $1.49M.
  • Recursion Pharmaceuticals made up ﹤0.01% of Bank of America's portfolio in Q1 2026, its #3151 holding.
  • Bank of America first reported a position in Recursion Pharmaceuticals in Q2 2021 and has held it in 20 quarters since.
  • Bank of America's Recursion Pharmaceuticals position peaked at $17M in Q1 2024.
  • 335 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.